Lantheus Holdings Inc (LNTH) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $100.74 (-0.06%), Market cap $6.04B, P/E ratio 22.13, 52-week low–high $50.11 ~ $96.67.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18
Financial statements, price targets, institutional (13F) holdings and related news for Lantheus Holdings Inc are updated in real time on BlackAll Trade.
Lantheus Holdings Inc trades at $100.74 (-0.06%). Real-time quotes and charts are available on BlackAll Trade.
Lantheus Holdings Inc has a market cap of about $6.04B. Its P/E ratio is 22.13.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.